Healthcare Stocks Surge in After-Hours Trading: KYMR, OCUL, POAI Lead the Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy KYMR?
Source: NASDAQ.COM
Kymera Therapeutics Inc.: The company's shares surged 9.58% to $73.00 in after-hours trading, driven by anticipation of results from the BroADen Phase 1b clinical trial for its oral STAT6 degrader for atopic dermatitis, set to be announced on December 8.
Ocular Therapeutix Inc.: Shares increased by 11.29% to $14.00 after hours, following recent progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, despite no new updates on Friday.
Predictive Oncology Inc.: The stock jumped 13.62% to $4.84 after hours, rebounding from a significant decline during the day, as the company regained compliance with Nasdaq's minimum stockholders' equity requirement.
Acumen Pharmaceuticals Inc.: Shares rose 3.23% to $1.92 after hours, following a presentation at the CTAD conference on improved delivery of Alzheimer's treatment antibodies, indicating positive long-term development prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KYMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KYMR
Wall Street analysts forecast KYMR stock price to rise
22 Analyst Rating
21 Buy
1 Hold
0 Sell
Strong Buy
Current: 86.350
Low
90.00
Averages
116.30
High
138.00
Current: 86.350
Low
90.00
Averages
116.30
High
138.00
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of KYMR Options Trading Dynamics
- Options Selling Risks: Selling puts on KYMR does not provide investors with the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, and unless KYMR's shares decline by 31.3%, the only benefit is a 15.1% annualized return from the premium.
- Cost Basis Analysis: If the contract is exercised, the seller's cost basis would be $52.80 per share after deducting the $7.20 option fee, indicating a mismatch between risk and reward when selling puts at the current market price.
- Volatility Assessment: With a trailing twelve-month volatility of 74% for KYMR, this metric, combined with fundamental analysis, can assist investors in determining whether selling the December put at a $60 strike price is worthwhile, especially given the current stock price of $87.93.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
Kymera Therapeutics (KYMR.US) Insider Plans to Sell $18.27 Million in Common Stock via Form 144
Company Announcement: Kymera Therapeutics plans to sell 200,000 shares of its common stock on March 2.
Market Value: The total market value of the shares being sold is approximately $18.27 million.
See More
Piper Sandler Raises Kymera Price Target to $140 on Strong Clinical Data
- Analyst Rating Upgrade: Piper Sandler raised Kymera Therapeutics' price target from $125 to $140, reflecting strong confidence in its oral protein degraders, which is expected to drive the company's stock price higher.
- Clinical Data Support: Early clinical data indicates that Kymera's STAT6 degrader program can achieve biologic-like pathway suppression in a convenient and scalable oral formulation, further solidifying its position as a category leader.
- Market Competitive Advantage: Piper believes that Kymera's first-mover advantage in immunology degraders and oral differentiation compared to biologics provide an attractive risk-reward profile in the current market environment.
- Optimistic Investment Outlook: With expanding clinical evidence, Piper Sandler maintains an optimistic view on Kymera's future performance, believing it has significant growth potential in the emerging oral atopic dermatitis market.
See More
Kymera Therapeutics Highlights Q4 2025 Earnings Call
- Significant R&D Progress: Kymera Therapeutics achieved a breakout year in 2025, with CEO Mainolfi highlighting outstanding results from KT-621's clinical trials, expecting to share data by mid-2027, indicating substantial potential in the atopic dermatitis market that could drive market share growth.
- Strong Financial Position: The company ended the year with a cash balance of $1.6 billion, with CFO Jacobs reporting collaboration revenue of $2.9 million in Q4 and R&D expenses of $83.8 million, showcasing a robust financial foundation to support future R&D plans and market expansion.
- New Partnerships Established: Kymera formed a new partnership with Gilead focusing on the CDK2 molecular glue program, while ongoing collaboration with Sanofi continues, which will provide additional revenue streams and technical support, enhancing competitive positioning in the market.
- Strategic Leadership Change: The appointment of Neil Graham as the new Chief Development Officer, who previously led the dupilumab project at Regeneron, is expected to bring fresh perspectives and experience to the company's R&D strategy, further accelerating product development efforts.
See More
Kymera Therapeutics Set to Announce Q4 Earnings
- Earnings Announcement: Kymera Therapeutics (KYMR) is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of -$0.79, reflecting a 10.2% year-over-year improvement, indicating slight progress in profitability.
- Strong Revenue Expectations: The anticipated Q4 revenue of $14.8 million represents a 100% year-over-year increase, showcasing significant growth in market demand and product sales, which could positively impact the stock price.
- Performance Forecast Changes: Over the past year, KYMR has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, suggesting growing market confidence in its performance, although there is still room for improvement.
- Valuation and Financing Dynamics: Kymera recently completed a $602 million public offering at $86.00 per share and proposed an additional $500 million fundraising plan, reflecting market recognition of its future growth potential while providing necessary funding for R&D and operations.
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported an increase of 2,005,813 shares in Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Value Growth: The fund's quarter-end position in Kymera rose by $297.15 million, reflecting both trading activity and share price appreciation, which suggests heightened market recognition of Kymera's potential.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, up 130% over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: Kymera entered 2026 with approximately $1.6 billion in cash, supporting its leading oral therapies pipeline in immunology and oncology, and positive clinical trial results could further enhance its market valuation.
See More
Analysis of KYMR Options Trading Dynamics
- Options Selling Risks: Selling puts on KYMR does not provide investors with the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, and unless KYMR's shares decline by 31.3%, the only benefit is a 15.1% annualized return from the premium.
- Cost Basis Analysis: If the contract is exercised, the seller's cost basis would be $52.80 per share after deducting the $7.20 option fee, indicating a mismatch between risk and reward when selling puts at the current market price.
- Volatility Assessment: With a trailing twelve-month volatility of 74% for KYMR, this metric, combined with fundamental analysis, can assist investors in determining whether selling the December put at a $60 strike price is worthwhile, especially given the current stock price of $87.93.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
Kymera Therapeutics (KYMR.US) Insider Plans to Sell $18.27 Million in Common Stock via Form 144
Company Announcement: Kymera Therapeutics plans to sell 200,000 shares of its common stock on March 2.
Market Value: The total market value of the shares being sold is approximately $18.27 million.
See More
Piper Sandler Raises Kymera Price Target to $140 on Strong Clinical Data
- Analyst Rating Upgrade: Piper Sandler raised Kymera Therapeutics' price target from $125 to $140, reflecting strong confidence in its oral protein degraders, which is expected to drive the company's stock price higher.
- Clinical Data Support: Early clinical data indicates that Kymera's STAT6 degrader program can achieve biologic-like pathway suppression in a convenient and scalable oral formulation, further solidifying its position as a category leader.
- Market Competitive Advantage: Piper believes that Kymera's first-mover advantage in immunology degraders and oral differentiation compared to biologics provide an attractive risk-reward profile in the current market environment.
- Optimistic Investment Outlook: With expanding clinical evidence, Piper Sandler maintains an optimistic view on Kymera's future performance, believing it has significant growth potential in the emerging oral atopic dermatitis market.
See More
Kymera Therapeutics Highlights Q4 2025 Earnings Call
- Significant R&D Progress: Kymera Therapeutics achieved a breakout year in 2025, with CEO Mainolfi highlighting outstanding results from KT-621's clinical trials, expecting to share data by mid-2027, indicating substantial potential in the atopic dermatitis market that could drive market share growth.
- Strong Financial Position: The company ended the year with a cash balance of $1.6 billion, with CFO Jacobs reporting collaboration revenue of $2.9 million in Q4 and R&D expenses of $83.8 million, showcasing a robust financial foundation to support future R&D plans and market expansion.
- New Partnerships Established: Kymera formed a new partnership with Gilead focusing on the CDK2 molecular glue program, while ongoing collaboration with Sanofi continues, which will provide additional revenue streams and technical support, enhancing competitive positioning in the market.
- Strategic Leadership Change: The appointment of Neil Graham as the new Chief Development Officer, who previously led the dupilumab project at Regeneron, is expected to bring fresh perspectives and experience to the company's R&D strategy, further accelerating product development efforts.
See More
Kymera Therapeutics Set to Announce Q4 Earnings
- Earnings Announcement: Kymera Therapeutics (KYMR) is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of -$0.79, reflecting a 10.2% year-over-year improvement, indicating slight progress in profitability.
- Strong Revenue Expectations: The anticipated Q4 revenue of $14.8 million represents a 100% year-over-year increase, showcasing significant growth in market demand and product sales, which could positively impact the stock price.
- Performance Forecast Changes: Over the past year, KYMR has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, suggesting growing market confidence in its performance, although there is still room for improvement.
- Valuation and Financing Dynamics: Kymera recently completed a $602 million public offering at $86.00 per share and proposed an additional $500 million fundraising plan, reflecting market recognition of its future growth potential while providing necessary funding for R&D and operations.
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported an increase of 2,005,813 shares in Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Value Growth: The fund's quarter-end position in Kymera rose by $297.15 million, reflecting both trading activity and share price appreciation, which suggests heightened market recognition of Kymera's potential.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, up 130% over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: Kymera entered 2026 with approximately $1.6 billion in cash, supporting its leading oral therapies pipeline in immunology and oncology, and positive clinical trial results could further enhance its market valuation.
See More
